InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.018 -0.02 (-52.63%)+
Announcement
Release
30 Jan 2026 9:48AM
Price at Release
$0.038
Full Release
download
Summary
Atomo Diagnostics Limited announced a significant order for its HIV Self-Test products, valued at A$416,000, to be supplied to an African country. The order is funded by the Global Fund and represents material revenue for the company. This is the second such order from the Global Fund in 2026, following a previous order announced earlier in January. Atomo's Managing Director, John Kelly, expressed enthusiasm about the growing global demand for their HIV Self-Test and the company's plans to expand its HIV business in the upcoming year.
Key Points
  • Atomo Diagnostics Limited secures a significant order for HIV Self-Tests.
  • The order is valued at A$416,000 and will be supplied to an African country.
  • The order is funded by the Global Fund.
  • This is the second Global Fund order in 2026.
  • Atomo considers the revenue from this order to be material.
  • Managing Director John Kelly highlighted global demand and future growth plans.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.